Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 1,82 € ( 30,00 %). Der Median liegt bei 1,82 € ( 30,00 %).
Kaufen |
1 |
Halten |
0
|
Verkaufen |
0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
- 03.10. - 10:55 Uhr
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
Clinic to serve as the prototype for HOPE's network of Interventional Psychiatric Clinics Nationally recognized founder to become Chief Medical Innovation Officer of HOPE, in order to implement and evolve the Company's standard of care across the HOPE network Acquisition would be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI , Oct. 3, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of a premier West Coast Interventional Psychiatric Clinic. Importantly, as a component of the acquisition, the founder of the clinic, a pioneer and nationally recognized leader in the use of advanced treatments for treatment of CNS disorders, has agreed to join HOPE as Chief Medical Innovation Officer (CMIO). » Mehr auf prnewswire.com
- 30.09. - 11:00 Uhr
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine)
Stability milestone supports submission of FDA New Drug Application by NRx for the use of intravenous ketamine to treat Suicidal Depression Ketamine is currently used off-label for this indication. However, FDA approval is typically required for patients to obtain insurance reimbursement NRX-100 is the first preservative-free formulation of Ketamine, potentially avoiding toxic side effects of preservatives used in current preparations designed for single dose anesthetic use RADNOR, Pa. » Mehr auf prnewswire.com
- 11.09. - 11:55 Uhr
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com
"How NRx Could Upend the Fight Against Depression and Suicide" RADNOR, Pa. , Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. » Mehr auf prnewswire.com
Unternehmenszahlen
(EUR) | Juni 2024 | |
---|---|---|
Umsatz | 0,00 | - |
Bruttoeinkommen | 931,53 | 1,69% |
Nettoeinkommen | 7,36 Mio | 7,88% |
EBITDA | 6,57 Mio | 10,87% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 15,07 Mio € |
Anzahl Aktien | 10,75 Mio |
52 Wochen-Hoch/Tief | 6,67 € - 1,36 € |
Dividenden | Nein |
Beta | 1,25 |
KGV (PE Ratio) | 0,65 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,88 |
KUV (PS Ratio) | 2.069,28 |
Unternehmensprofil
NRX Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen in der klinischen Phase und entwickelt neuartige Therapeutika für die Behandlung von Erkrankungen des zentralen Nervensystems und lebensbedrohlichen Lungenkrankheiten. Zu seinen Produkten gehören ZYESAMI, ein Prüfpräparat, das eine klinische Studie der Phase IIb/III zur Behandlung von COVID-19-bedingtem Atemversagen abgeschlossen hat, sowie die oralen Therapeutika NRX-100 und NRX-101 zur Behandlung bipolarer Depressionen bei Patienten mit akuter Suizidalität und subakuten Suizidgedanken und -verhaltensweisen. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Sitz in Wilmington, Delaware.
Name | BIG ROCKPAR |
CEO | Stephen H. Willard Esq. |
Sitz | Wilmington,
de USA |
Website | |
Industrie | Chemikalien |
Börsengang | 04.12.2017 |
Mitarbeiter | 2 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | NRXP |
Assets entdecken
Shareholder von BIG ROCKPAR investieren auch in folgende Assets